TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02294955

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Catheterablation
Description: Pulmonary vein isolation using either Arctic Front™ Cardiac CryoAblation or irrigated radiofrequency catheter ablation. A linear lesion, a left atrial roof line, is optional for patients with AF recurrence after a first procedure or primarily for patients with persistent AF.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amiodarone
Description: Dosage orally 600 mg once daily for 7-10 days, and 100-200 mg once daily thereafter.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sotalol
Description: Dosage orally 80-160 mg twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flecainide
Description: Dosage orally 100 to 150 mg twice daily or the entire dose as slow-release formula once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propafenone
Description: Dosage orally 300 mg twice daily
Study: NCT02747602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC-1204
Description: 40 g (120 mL) AC-1204 administered 30 minutes after the start of a standard breakfast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: caprylic triglyceride oil (standard breakfast)
Description: 20 g CT oil (21 mL) administered 30 minutes after the start of a standard breakfast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: caprylic triglyceride oil (standard breakfast)
Description: 20 g CT oil (21 mL) administered 30 minutes after the start of a standard breakfast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: caprylic triglyceride oil (standard breakfast)
Description: 20 g CT oil (21 mL) administered 30 minutes after the start of a standard breakfast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: caprylic triglyceride oil (high fat breakfast)
Description: 20 g CT oil (21 mL) administered 30 minutes after the start of a high fat breakfast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: caprylic triglyceride oil (high fat breakfast)
Description: 20 g CT oil (21 mL) administered 30 minutes after the start of a high fat breakfast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: caprylic triglyceride oil (high fat breakfast)
Description: 20 g CT oil (21 mL) administered 30 minutes after the start of a high fat breakfast.
Study: NCT01787760

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Soft Contact Lens B
Description: Test lenses to be worn in daily wear modality

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Soft Contact Lens C
Description: Test lenses to be worn in a daily wear modality

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator
Description: Control spectacle lenses to be worn in a daily wear modality
Study: NCT01348880

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vardenafil ODT, (Staxyn, BAY38-9456)
Description: Single dose of 10 mg of vardenafil ODT, taken without water

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose of placebo to match 10 mg vardenafil ODT. taken without water
Study: NCT01029717

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard polyurethane Central Venous Catheter
Description: Standard polyurethane Central Venous Catheter, All CVCs used in the trial are CE marked medical devices used for their intended purpose.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotic impregnated polyurethane CVC (minocycline and rifampicin)
Description: Antibiotic impregnated polyurethane CVC (minocycline and rifampicin. All CVCs used in the trial are CE marked medical devices used for their intended purpose.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Heparin bonded polyurethane CVC
Description: Heparin bonded polyurethane CVC. All CVCs used in the trial are CE marked medical devices used for their intended purpose.
Study: NCT03413748

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Elective Cesarean Section
Description: lower segment cesarean section

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Elective Cesarean Section
Description: lower segment cesarean section

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Peritoneal irrigation
Description: Irrigation of peritoneal cavity with 500 - 1000 ml of warm normal saline
Study: NCT03477149

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Easyx
Description: Embolization will be done with Easyx liquid agent.
Study: NCT01656096

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Renal sympathetic denervation (Symplicity ablation catheter, Medtronic Inc. Minneapolis, Minnesota, USA)

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham procedure
Study: NCT04114968

Intervention type: OTHER
Intervention: GP-based screening or HPV self-sampling
Description: Women in the intervention group will receive an invitation for HPV-based cervical cancer screening by either 1) scheduling an appointment for a cervical cytology by the GP or 2) collect a cervico-vaginal sample themselves in their own home using a self-sampling kit.
Study: NCT00319228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plasma-derived AT-III concentrate
Description: Segment I: A single dose IV infusion of 50 IU/kg of ATIII-DAF/DI will be administered to each patient.~Segment II: A single dose or multiple doses depending on the subject's ATIII plasma levels and patient's specific treatment plan.
Study: NCT01469494

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: DIEP flap breast reconstruction
Description: DIEP stands for deep inferior epigastric perforator. This is the name of the main blood vessel that runs through the abdominal tissue that will be used to reconstruct the breast. In DIEP flap reconstruction, only skin, fat, and blood vessels are removed from the lower belly (the abdomen between the waist and hips). No muscle is removed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SIEA flap breast reconstruction
Description: The SIEA flap is very similar to the DIEP flap procedure. Both techniques use the lower abdominal skin and fatty tissue to reconstruct a natural, soft breast following mastectomy.~The main difference between the SIEA flap and the DIEP flap is the artery used to supply blood flow to the new breast. The SIEA blood vessels are found in the fatty tissue just below skin whereas the DIEP blood vessels run below and within the abdominal muscle (making the surgery more technically challenging). While the surgical preparation is slightly different, both procedures spare the abdominal muscle and only use the patient's skin and fat to reconstruct the breast.
Study: NCT01628250

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic complete mesocolic excision
Description: laparoscopic complete mesocolic excision would be applied on randomized group of patients suffering colon cancer and possessing no marked surgical anti-indications. Lap.CME facilitaes medial approach to complete the procedure. CME and HMA are the two arms of the medial approach utilized.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: D3-laparoscopic colectomy
Description: D3-laparoscopic colectomy would be applied on randomized group of patients suffering colon cancer and possessing no marked surgical anti-indications.
Study: NCT02214316

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypertonic Saline
Study: NCT02833116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betamethasone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Study: NCT03251287

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Nitrate
Description: Single dose of 14mmol oral inorganic sodium nitrate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose of oral matching placebo

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Phosphorous Magnetic Resonance Spectroscopy
Description: On the first visit day of this arm, participants will be lie inside an MRI scanner to take pictures of the heart. The thigh muscle will then be imaged before, during, and after kicking exercises.
Study: NCT03801499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: 12 mg (or 8 mg) once daily (QD) oral dosing.
Study: NCT04408937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: triopifexor
Description: Tropifexor as a dry blend in hard gelatin capsules for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: triopifexor
Description: Tropifexor as a dry blend in hard gelatin capsules for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo capsules for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo capsules for oral administration
Study: NCT02021799

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Moringa and Lactobacillus rhamnosus GR-1

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Moringa and Lactobacillus rhamnosus GR-1
Study: NCT01039142

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acitretin
Description: capsule acitretin in dose of 25 mg, 35 mg or 50 mg/ day for 12 weeks or reduction in PASI score by 75% whichever is earlier

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acitretin
Description: capsule acitretin in dose of 25 mg, 35 mg or 50 mg/ day for 12 weeks or reduction in PASI score by 75% whichever is earlier

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acitretin
Description: capsule acitretin in dose of 25 mg, 35 mg or 50 mg/ day for 12 weeks or reduction in PASI score by 75% whichever is earlier
Study: NCT01535144

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fracture compressing screw ZfW 102 Königsee Implantate GmbH
Description: Comparison of two metallic implantable fracture compressing screws

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fracture compressing screw titanium Königsee Implantate GmbH
Description: Comparison of two metallic implantable fracture compressing screws
Study: NCT02205307

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PINPOINT

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SPY Elite
Study: NCT01353963

Intervention type: DRUG
Intervention: desvenlafaxine succinate
Description: 50 mg tablet once daily
Study: NCT00993369

Intervention type: OTHER
Intervention: Holter monitor
Description: Record heart rate for 2 to 6 hours on day of life 1 or 2.

Intervention type: OTHER
Intervention: Holter monitor
Description: Record heart rate for 2 to 6 hours on day of life 1 or 2.
Study: NCT00764231

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based exercise program
Description: Subjects will be given a personalized 12-week exercise program consisting of cardiovascular, musculoskeletal and flexibility exercises by a certified exercise physiologist. They will receive fitness assessments at baseline, 6 weeks and 12 weeks.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Wait list
Description: Subjects will have a 12-week waiting period, during which time they will be asked not to change their exercise habits. These subjects will receive the same fitness assessments as the experimental group (baseline, 6 weeks, 12 weeks), but will not receive an exercise program during the wait-list period. Following the 12-week wait-list period, subjects will be given the same home-based exercise intervention as the experimental group.
Study: NCT03799536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotalol
Description: Sotalol, Tablets,160 mg, manufactured by Pharmtechnology LLC, Belarus
Study: NCT02445209

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: EOX
Description: combined chemotherapy regimen: epirubicin + oxaliplatin + capecitabine
Study: NCT03799536

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sotalex
Description: Sotalex, Tablets,160 mg, manufactured by Bristol-Myers Squibb GmbH \& Co. KGaA, Germany
Study: NCT00617201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atomoxetine
Description: Once daily oral dosing

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Once daily oral dosing - matched placebo
Study: NCT00856505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus and mycophenolate sodium
Description: Everolimus tablets, 1.5mg/day bid, dosage adjusted to plasma levels Mycophenolate sodium, 720mg/day bid Duration: Mycophenolate tapering starts at day 56 after stem cell transplantation Everolimus tapering starts at day 100 after stem cell transplantation if no GvHD evident
Study: NCT03251287

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Phosphorous Magnetic Resonance Spectroscopy
Description: On the first visit day of this arm, participants will be lie inside an MRI scanner to take pictures of the heart. The thigh muscle will then be imaged before, during, and after kicking exercises.

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Exercise Stress Transthoracic Echocardiogram
Description: On the second visit day of this arm, participants will be asked to lie, semi-erect, on an exercise bed for up to 90 minutes. The echocardiogram will be performed at rest and during peak exercise. The exercise will be in the form of a pedal bike. The exercise levels will be worked out from an upright bicycle exercise test completed by the participants prior to randomization.
Study: NCT04377048

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: as described in NGS Arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: as described in NGS Arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegafur-Gimeracil-Oteracil
Description: as described in NGS Arm
Study: NCT02855619

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Martin
Description: The physiotherapist perform the IMT using the threshold IMT inspiratory muscle trainer, connected to the intubation tube. He manage the resistance to the higher resistance tolerated by the patient in a set of 6 breaths. Participant repeats 4 sets of 6-10 breaths with 2 minutes of resting with mechanical ventilation between each set.~This treatment is made twice a day, 7days per week from inclusion to extubation exept if Glasgow score is under 8, hyperthermia more than 39°c, haemodynamic's instability, or hypoxemia( PaO2/FiO2\<150).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cader
Description: The physiotherapist perform the IMT using the threshold IMT inspiratory muscle trainer, connected to the intubation tube. He manage the resistance to 30% of the Maximal Inspiratory Pressure initially recorded the day of the inclusion. Participant breaths against this resistance during 5 minutes. The resistance is daily increased of 10 % to the higher tolerated.~This treatment is made twice a day, 7days per week from inclusion to extubation exept if Glasgow score is under 8, hyperthermia more than 39°c, haemodynamic's instability, or hypoxemia( PaO2/FiO2\<150).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EDRIC
Description: The physiotherapist perform the IMT using the threshold IMT inspiratory muscle trainer, connected to the intubation tube. He manage the resistance at 30% of the Maximal Inspiratory Pressure of the day for the first set of 20 breaths with a resistance 's increasment of 10% at each set. Participant repeats 4 sets of 20 breaths with 2 minutes of resting with mechanical ventilation between each set.~This treatment is made twice a day, 7days per week from inclusion to extubation exept if Glasgow score is under 8, hyperthermia more than 39°c, haemodynamic's instability, or hypoxemia( PaO2/FiO2\<150).
Study: NCT00478452

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DC-Ova

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DC Ova with Cyclophosphamide
Study: NCT01005329

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo IMRT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study: NCT03944681

Intervention type: DRUG
Group type: OTHER
Intervention: Droperidol Injectable Solution
Description: An electrocardiogram analysis in: 5,10,15,20 minutes after injection of 1.25 mg of droperidol used as PONV prophylaxis.
Study: NCT03251287

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Stress Transthoracic Echocardiogram
Description: On the second visit day of this arm, participants will be asked to lie, semi-erect, on an exercise bed for up to 90 minutes. The echocardiogram will be performed at rest and during peak exercise. The exercise will be in the form of a pedal bike. The exercise levels will be worked out from an upright bicycle exercise test completed by the participants prior to randomization.
Study: NCT04855448

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Micro Hand S robot and da Vinci robot
Description: The surgeries are performed with the Micro Hand S robot and da Vinci robot

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: da Vinci robot
Description: The surgeries are performed with the da Vinci robot
Study: NCT03121014

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 40 mg/m\^2 IVBP daily for day -5 (5 days before stem cell infusion) through Day -2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: targeting a 4800μM/min/ day from day -5 through day -2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG
Description: 0.5 mg/kg IV on day -3, and 2 mg/kg on days -2 and day -1

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Marrow Irradiation
Description: dose of 3Gy on days -3, -2 and -1

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell Product Infusion
Description: Day 0 according to BMT unit policy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: The starting dose is at 0.03 mg/kg/day IV continuous infusion over 24 hr from 4 PM on day -2. Dose will be adjusted to target trough levels of 5-15 ng/mL. More information is available in the protocol document.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: 5mg/m\^2 on Day 1, 5 mg/m\^2 on Days 3, 6 and 11
Study: NCT03331614

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Flowaid FA-100 SCCD
Description: The SCCD is a contained external non invasive electric muscle pump. The device attaches to the rear of the calf with 4 electrodes.
Study: NCT02282202

Intervention type: DEVICE
Group type: OTHER
Intervention: Oscillating Positive Expiratory Pressure (Aerobika ®)
Description: The oPEP system (Aerobika ®) combines positive expiratory pressure therapy and airway vibrations to help mobilize pulmonary secretions. oPEP therapy (Aerobika ®) enforces a resistance to exhalation at the mouth, while the airway vibration technology transmits movements upstream during exhalation so that airway walls may become free from mucous. Subjects will take home the device and use four times daily during the active part of the study.~There is only one intervention for this study. Subjects are on treatment for three weeks and off for the alternate three weeks.
Study: NCT01876849

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exenatide
Description: subcutaneous injection, 5mcg or 10 mcg, twice daily
Study: NCT03365999

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Tranexamic Acid
Description: Patients undergoing total knee replacement who will receive three doses of tranexamic acid administered orally (1 prior to surgery and 2 subsequent to surgery).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Aminocaproic Acid
Description: Patients undergoing total knee replacement who will receive three doses of aminocaproic acid administered orally (1 prior to surgery and 2 subsequent to surgery).
Study: NCT00617370

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epirubicin, cyclophosphamide, Paclitaxel,
Description: EC (epirubicin 100 mg/m2, cyclophosphamide 600 mg/m2) q 14 days x 6 treatments with pegfilgrastim SQ day # 2 (6 mg). Paclitaxel (175 mg/m2) q 14 days x 6 treatments with pegfilgrastim SQ day # 2 (6 mg).
Study: NCT04357613

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental drug
Description: Imatinib 800mg/d during 14days
Study: NCT01471899

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac Tromethamine
Description: 10 drops each 8 hours for 4 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen
Description: 2 tablets every 8 hours for 4 days
Study: NCT01421199

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Myringotomy
Description: tube placement for children with multiple ear infections
Study: NCT06427902

Intervention type: OTHER
Intervention: Periodontal clinical measurements, Saliva sampling
Description: Clinical periodontal indices; Probing depth, Clinical attachment level, bleeding on probing, gingival index, and plaque

Intervention type: OTHER
Intervention: Periodontal clinical measurements, Saliva sampling
Description: Clinical periodontal indices; Probing depth, Clinical attachment level, bleeding on probing, gingival index, and plaque

Intervention type: OTHER
Intervention: Periodontal clinical measurements, Saliva sampling
Description: Clinical periodontal indices; Probing depth, Clinical attachment level, bleeding on probing, gingival index, and plaque
Study: NCT04530279

Intervention type: PROCEDURE
Intervention: Clinical assessment
Description: Clinical assessment of burn depth and the percentage of total body surface area (TBSA) burnt with any method

Intervention type: PROCEDURE
Intervention: Clinical assessment
Description: Clinical assessment of burn depth and the percentage of total body surface area (TBSA) burnt with any method
Study: NCT03973099

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PM011
Description: PM011 is a 400 mg hard gelatin capsule containing water extracts of Nelumbinis Semen. The sprayed-dry extract of the herbal medicine used was purchased from Sun Ten pharmaceutical company in Taiwan. Each participant received twelve capsules of PM011, which divided into 2.4 g treatment or 4.8 g treatment group or placebo daily for two weeks and was instructed to take six capsules after breakfast and six capsules after dinner. Subjects in the placebo group received the equivalent amount of starch and lactose mixture capsules and administered with the same schedule.
Study: NCT03426839

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Coagulation tests

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Coagulation tests